Takeda’s oral multiple myeloma drug narrowly misses in Phase III study
Results of the study of Ninlaro in newly diagnosed patients ineligible for transplant did not reach statistical significance. The announcement came a day after Bristol-Myers Squibb announced the failure of a study in the same disease setting.